Intel Is Worth More Than Coca-Cola and PepsiCo Put Together
A chipmaker that lost billions last year now commands a valuation that dwarfs two of the world's most profitable consumer giants, and the math holding that together is razor thin.
Archive
Year: 2026
All Year: 2026 Articles
Newest first · Page 198
AMD Turned $10,000 Into More Than $1.2 Million. Can It Happen Again?
A $10,000 bet on AMD in 2011 grew into more than $1.2 million, but the AI boom that sent shares soaring 211% in a single year raises a harder question: how much runway is…
5 Dividend Stocks That Turn Small Annual Raises Into Serious Long-Term Income
A dividend that grows beats one that just pays, but only if the raise keeps coming year after year. These five industrials have done exactly that, and the math behind their payout records reveals…
Humana Soars 16% on Improved Medicare Advantage Star Ratings; CVS Slides 3%, UnitedHealth Holds Steady
A single Medicare quality ratings release sent one major insurer soaring while dragging a rival into the red, and the gap between winners and losers points to something deeper than a routine scoring update.
Optics Stocks Rally on Sold-Out Optical Capacity Through Early 2029: Applied Optoelectronics and Lumentum Surge 7%, Coherent Climbs 5%
Optical component makers just received a demand signal so strong it reversed weeks of profit-taking in a single morning session, and the company behind it says its order book now stretches years into the…
SpaceX Climbs 4% on Nationwide Low-Band Spectrum Deal for Starlink Mobile; Verizon and AT&T Drop 7%
SpaceX just bought something it cannot launch, and the move sent two of America's biggest wireless carriers into a sudden selloff. Here is what the spectrum purchase means for anyone holding carrier stock.
3 Chip and Software Giants Paid Dividends on the Same Day. 1 Hasn’t Raised Its Payout Since 2023.
Three chip and software giants sent dividend checks to shareholders on the same day, but their records tell very different stories about which boards are sharing their growth and which are quietly holding out.
4 Dividend Stocks Boomers Can Safely Buy Now and Hold Forever
Four Dividend Kings with streaks stretching back decades sit inside millions of retirement portfolios, but one of them is spending every dollar of free cash flow just to keep its streak alive. Here is…
From 2020 Collapse to 80% Payout Ratio: Is GLPI’s Dividend Truly Bulletproof?
GLPI slashed its dividend to nearly nothing when casinos went dark in 2020, yet management now calls gaming revenues bulletproof. With one master lease sitting at a coverage ratio that leaves little room for…
Peter Lynch Beat the Market for 13 Years, Then Said Most Investors Should Just Buy an Index Fund
The greatest stock picker of his generation handed ordinary investors a confession that cost him nothing and could save them six figures. What he said, and why the math behind it is harder to…
Goldman Sachs’ Top Bosses Are in Line for $500 Million in Special Stock Awards
Goldman Sachs awarded performance stock to its top executives back in 2021, and three years of share price gains have quietly turned those grants into something much larger than anyone publicly discussed at the…
Here Are Friday’s Top Wall Street Analyst Research Calls: American Express, Archer Aviation, Fastly, Jack Henry & Associates, Joby Aviation, Lockheed Martin, Palantir, Rocket Lab, SpaceX and More
Futures bounced back Friday after AI stocks took a beating on weak OpenAI revenue, oil prices surged past $103, and Bitcoin cratered below $81,000. See which analysts rewrote the playbook on Palantir, Rocket Lab,…
The XRP Ledger Surpasses Ethereum in a Key Area. What Does This Mean for the XRP Price?
The XRP Ledger just beat Ethereum in a major tokenization category, yet XRP holders are watching their coin bleed value. Something is breaking the connection between ledger success and price, and the answer reveals…
Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks
Cantor Fitzgerald just bumped price targets on Eli Lilly, AbbVie, Merck, and Pfizer, but higher targets do not mean equal conviction. The firm's split between Overweight and Neutral ratings reveals a sharp divide in…
Lam Research Transformed $1,000 Into $37,462 Over Ten Years Despite Three 40% Crashes
Lam Research turned a modest stake into a life-changing sum over ten years, but the ride included three gut-wrenching collapses that pushed most investors to bail out long before the biggest gains arrived.